Drug intelligence / Profile preview

CHF 1535 + tiotropium

Development stage: Unknown
Lead developer: Chiesi
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Inhalation

Overview

CHF 1535 + tiotropium is a combination therapy investigated for the treatment of chronic obstructive pulmonary disease (COPD). CHF 1535 is an inhaled fixed-dose combination under development by Chiesi, while tiotropium is a long-acting muscarinic antagonist (LAMA) widely used in COPD management. Tiotropium works by antagonizing muscarinic acetylcholine receptors (primarily M3) in airway smooth muscle, leading to bronchodilation and improved airflow[1][6][8]. The combination aims to enhance efficacy in reducing COPD exacerbations and improving lung function compared to monotherapy. Clinical studies have evaluated this combination using pressurized metered dose inhalers (pMDI) and other delivery devices[3][5].

Brand names: Spiriva RespimatSpiriva HandiHaler

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)ADRB2 (β2)CHRM3 (M3)

Beyond the preview

Go deeper on CHF 1535 + tiotropium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHF 1535 + tiotropium.

Explore the full profile